AN2 Therapeutics Advances Chagas Disease and Oncology Programs and Reports Third Quarter 2025 Results
Reuters
Nov 13
AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances Chagas Disease and Oncology Programs and Reports Third Quarter 2025 Results
AN2 Therapeutics Inc. announced its third quarter 2025 financial results and recent business and scientific highlights. The company reported ongoing progress in its clinical pipeline, including the advancement of a Phase 1 first-in-human clinical trial for oral AN2-502998 targeting Chagas disease, with planning underway for a subsequent Phase 2 proof-of-concept study in collaboration with the Drugs for Neglected Diseases initiative (DNDi). The clinical-stage M. abscessus program is advancing through an investigator-initiated trial. In oncology, AN2 expects its first of two boron-based oncology targets to enter development in early 2026, with both programs aimed at solid-tumor cancers. AN2 also announced a research collaboration with GSK to develop boron-based LeuRS-inhibitors for tuberculosis (TB) and received a third year of funding from the Gates Foundation to support this work.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-277662), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.